Consistent with its strategy of expanding in the international arena, Qiagen (NASDAQ:QGEN) recently obtained the regulatory approval for its therascreen EGFR Mutation Detection Kit RGQ in Japan. Japan has emerged as the leading companion diagnostics market in the world and this approval holds immense potential for Qiagen to further expand in this segment.
EGFR or the epidermal growth factor receptor has been proved to play an important role in certain cancers, thus helping guide cancer treatments. … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards